ライフサイエンスコーパス: poor

1 or refractory acute myeloid leukaemia remain poor.

2 ad, whereas TB and TR cell-to-cell spread is poor.

3 n where vaccine effectiveness was considered poor.

4 that during training, muscle activation was poor.

5 e productivity they experienced in utero was poor.

6 Mahalanobis distance matching was relatively poor.

7 vival in the previously published result was poor.

8 nd inefficient provision of resources to the poor.

9 s, in natural and engineered environments is poor.

10 oral bioavailabilities resulting from their poor absorption, poor solubility, high first-pass metabo

11 One percent showed poor acuity (>=20/200) in the better-seeing eye, 12% in

12 eity can differentiate metastases from lipid-poor adenomas.

13 e over the course of the trial, resulting in poor adherence to the assigned study treatment and a red

14 Given the prevalence of poor adherence to therapy and the biases of self-reporti

15 g >=1 glaucoma medication, who self-reported poor adherence) completed a baseline survey that assesse

16 hird had drug concentrations consistent with poor adherence, highlighting the need for novel approach

17 particularly for microcephaly infants, were poor after birth but showed improvement beyond 4 months

18 ith the loss of cell surface protrusions and poor aggregation, resulting in increased dissemination o

19 minant validity, but limited reliability and poor agreement with a reference method.

20 ted tropical disease predominately affecting poor and marginalized populations.

21 r mild conditions even though it is electron-poor and not low-coordinate.

22 ression data exist, but annotation rates are poor and the ability to carry out true functional tests

23 benefit of PAH treatment, prognosis remains poor, and double-lung transplantation is an option for e

24 al in patients with relapsed disease remains poor, and thus novel therapeutic approaches are needed.

25 Poor aqueous solubility of some minor steviol glycosides

26 edical applications have been limited by its poor aqueous solubility.

27 medical advancements, it's prognosis remains poor as many patients with heart failure experience symp

28 Because poor B-cell reconstitution after hematopoietic stem cell

29 The group with poor BCVA had a higher proportion of non-White participa

30 cation using standard pathology as proxy for poor biology is associated with survival and response to

31 The risk of poor body weight gain increased in FPIES triggered by co

32 overy in NN dams, partial recovery in LN and poor bone recovery in LL dams.

33 Without therapy, prognosis is poor but treatments, typically immunosuppressants, have

34 he prognosis of HCM-LVSD has reportedly been poor, but because of its relative rarity, the natural hi

35 litate tumor proliferation and contribute to poor cancer outcomes.

36 Existing methods, however, commonly exhibit poor catalyst performance with high palladium (Pd) loadi

37 ve MALT1 have been reported, but suffer from poor cell permeability and/or cross-reactivity with the

38 As an explanation for the poor cell uptake of Ru360, we show that Ru360 is deactiv

39 cell or ribonuclease activation, leading to poor cell viability or RNA quality, which may impair ana

40 Both complications were associated with poor clinical outcome in a similar percentage of partici

41 n and epithelial markers and correlated with poor clinical outcome.

42 ed by N-MYC, is itself a strong predictor of poor clinical outcome.

43 ts tumor microenvironment (TME) is linked to poor clinical outcomes in treatment of resistant breast

44 CD73 levels in tumor tissues correlate with poor clinical outcomes.

45 med to explore the association of PM2.5 with poor cognitive function.

46 tobiotic mice include an adhesin enriched in poor colonizers.

47 ections are associated with higher costs and poor compliance and can hinder the implementation of glo

48 ints that are magnified in wildlife, such as poor control and substantial trait variation within and

49 Conventional prosthetic arms suffer from poor controllability and lack of sensory feedback.

50 c capacity, and fixed-cell microscopy showed poor convergence of lytic granules.

51 non-native substrates primarily resulted in poor conversions to anticipated macrolactones.

52 the context of comorbidities associated with poor COVID-19 outcomes.

53 creatic ductal adenocarcinoma (PDAC) remains poor despite decades of effort.

54 d maintain good therapeutic relationships is poor, despite this being a key aspect of the nursing rol

55 HOXA9 overexpression not only predicts poor diagnosis and outcome but also plays a critical rol

56 gher levels of sedentary behavior and also a poor diet quality score (cluster 3); and 4) a group with

57 In MICs and LICs, household air pollution, poor diet, low education, and low grip strength had stro

58 either disease onset/exacerbation due to a "poor" diet or protection against disease with a "healthy

59 core, the estimated proportion of youth with poor diets significantly declined from 76.8% (95% CI, 72

60 rioritize RAMS11 due to its association with poor disease-free survival and promotion of aggressive p

61 munosuppressive regimens have been used with poor disease-free survival at long-term follow-up.

62 natal seizures has changed minimally despite poor drug efficacy.

63 structure have superior strength but usually poor ductility.

64 ected that demonstration of low incidence of poor early graft outcomes and the presence of a "safety

65 pediatric solid tumors, but they often show poor efficacy due to intrinsic or acquired chemoresistan

66 h systems is still largely hampered by their poor electrical conductivities.

67 election because high ionic conductivity and poor electrochemical stability are typically observed in

68 The poor electronic conductivity of NaH is beneficial for th

69 Poor environmental conditions were associated with decli

70 e abandoned but this is especially likely in poor environments.

71 ws tit-for-tat retaliation is a surprisingly poor evolutionary strategy, because tit-for-tat cells la

72 ttrition rates in early clinical trials from poor exposure to drug safety concerns, such as drug-indu

73 Outcomes revealed decreased VA (10/32, 31%), poor final VA (17/32, 53%), good final VA (11/32, 34%),

74 istances but may end up in winter areas with poor fitness prospects.

75 of organisms, yet some of these models have poor fits to empirical data and lack of flexibility in c

76 Presenting symptoms were poor fixation and nystagmus.

77 Performance was similarly poor for calcium-enhanced broth microdilution.

78 Our results suggest that prognosis is poor for patients with Shwachman-Diamond syndrome and my

79 ," and genetic polymorphisms associated with poor fungal immunity could lead to a personalized assess

80 versity in microsatellites, but surprisingly poor geographical structuring.

81 ographically outward from these regions in a POOR-get-POORer fashion unless steps are taken to interr

82 We propose that interrupting the POOR-get-POORer progression of lung injury relies on two

83 , self-administered their eye drops, and had poor glaucoma medication adherence (defined as taking <=

84 the inflammation of T2D and associates with poor glycemic control and increased T2D morbidity.

85 he size and proximity of the nearest market, poor governance and the density of the human population.

86 ions (antagonism or synergism) in a nutrient-poor greenhouse soil.

87 patients with HCC, but also associated with poor HCC prognosis.

88 structural racism as a fundamental cause of poor health and disparities in cardiovascular disease.

89 th electron-withdrawing groups, and electron-poor heteroarenes, such as pyridine and pyrimidine, can

90 are a key initial mechanism associated with poor HIV control.

91 filtering-associated endophthalmitis remains poor; however, good visual and anatomic outcomes can be

92 uestionnaire items that were associated with poor HRQOL as identified by EORTC QLQ-C30 and QLQ-OG25 w

93 falls of increasing physician burnout due to poor implementation leading to added complexity.

94 Bowel preparation was poor in 19% of index colonoscopies, and only 36% of comp

95 hat proprioception of the knee joint is very poor in HSAN III but can be improved towards normal by a

96 tension is escalating, and control rates are poor in low- and middle-income countries.

97 ch as the borylation of C-H bonds, have been poor in many cases.

98 ils in central vision, whereas resolution is poor in our peripheral visual field, and this loss of re

99 fluenza vaccines (LAIVs) has been especially poor in recent years.

100 Patients with RVO demonstrating poor initial visual acuity showed visual and anatomic be

101 There was poor inter-rater reliability of Alpha/Beta classificatio

102 r junctions: series resistance of the leads, poor interface conductance, and low effective contact ar

103 nth discontinuation rates of tamoxifen among poor, intermediate, normal, and ultrarapid CYP2D6 metabo

104 among the general population is low, with a poor knowledge of alcohol consumption and dietary guidel

105 ts resulting in sustained MTOR signaling and poor lapatinib response.

106 Taken together, our findings indicate that poor LASV-specific T-cell responses and activation of no

107 HDL NPs are a cholesterol-poor ligand that binds to the receptor for cholesterol-r

108 Therein, upon proper design, the poor light absorption intrinsically featured by lanthani

109 ost people report feeling persistently 'time poor'-like they have too many things to do and not enoug

110 n and cerebral autoregulation asymmetry, and poor long-term clinical outcomes in acutely comatose pat

111 The complex underlying genetics and poor mechanistic understanding has caused a bottleneck i

112 ry constraint have remained elusive due to a poor mechanistic understanding of studied phenotypes.

113 ions that matched experimental data and were poor mediators of intensity-dependent gain control.

114 roportion of patients who then self-reported poor medication adherence than an automated EHR pull alo

115 By contrast, trisomic mice exhibited poor memory abilities and disordered prefrontal-hippocam

116 understanding of the development of risk for poor mental and physical health outcomes.

117 nation to methanol, causing low activity and poor methanol selectivity.

118 In resource-poor monocultures, the ants were top predators, sharing

119 the nuclear export of intronless and intron-poor mRNAs and lncRNAs.

120 m the experimental measurements and that the poor noise performance is due to the high RIN of the mid

121 nges in the Seebeck coefficient, switching a poor nonconventional p-type thermoelectric material, tel

122 We find that SWA decreases in water-poor northern China but increases in water-rich southern

123 idebenone to bypass Complex I in cells with poor NQO1 expression.

124 Furthermore, conditions that caused poor nucleosome positioning also led to defects in both

125 associated with development of diffuse WMI: poor oligodendrocyte maturation, diffuse axonal hypomyel

126 c atrophy and, further, its interaction with poor oral health elevated the risk of ESCC in a high-ris

127 odds of oral health problems, including fair/poor oral health status, mouth problems, and teeth probl

128 howed favorable performance for predicting a poor outcome (AUC > 0.750), and were better than the rad

129 proportion of participants with a composite poor outcome (defined as viral load >50 copies per mL, o

130 detect any combinations of events predicting poor outcome as defined by a cumulative CCI >=37.1 at 90

131 ment because of potential fetal harm risks a poor outcome for both mother and child.

132 One reason for this poor outcome has been that no treatment programme has ev

133 olume, and electrographic seizures predicted poor outcome in lobar intraparenchymal hemorrhage.

134 n ER(+ve)/luminal tumors was associated with poor outcome in luminal B cancers.

135 ion is associated with treatment failure and poor outcome in metastatic castration-resistant prostate

136 Poor outcome was defined as invasive ventilation and/or

137 One of these areas is the prediction of poor outcome, notably radiographic outcome in patients w

138 suppression and have been associated with a poor outcome.

139 The poor outcomes in esophageal adenocarcinoma (EAC) prompte

140 Modifiable risk factors associated with poor outcomes should prompt evidence-based interventions

141 urring mutations, high-risk presentation and poor outcomes were specific to multi-hit patients only.

142 sion B-cell acute lymphocytic leukaemia have poor outcomes when treated with regimens that do not con

143 up and/or adjuvant therapy to mitigate their poor outcomes.

144 treated clinically as a single disease with poor outcomes.

145 e arising in the mediastinum have distinctly poor outcomes.

146 we present evidence that infertile men have poor overall health and increased morbidity and mortalit

147 Metastatic uveal melanoma has poor overall survival (OS) and no approved systemic ther

148 Improper or poor oxygen supply to cells within the tissue bulk sever

149 ll cell lung cancer (NSCLC) is known to have poor patient outcomes due to development of resistance t

150 ncies, particularly pediatric leukemias with poor patient outcomes.

151 ccur frequently in CRC and are prognostic of poor patient outcomes.

152 ates with aggressive disease progression and poor patient prognosis.

153 6 pathway, which is strongly correlated with poor patient survival.

154 porosity, dendrites, and dead Li that cause poor performance and, all too often, spectacular failure

155 ses designed with QCTO method are limited to poor performance due to the presence of the reflections

156 am has the potential to predict and identify poor performance in real life.(C) RSNA, 2020Keywords: Br

157 CUs had an initial rhythm of bradycardia and poor perfusion.

158 difficulties including adverse toxicity and poor pharmacokinetic profiles.

159 Poor photoproduct yields are explained by donor-independ

160 ase (CKD) exhibit reduced exercise capacity, poor physical function and symptoms of fatigue.

161 unds display high binding affinity, but have poor physicochemical properties and are hence not suitab

162 e result of undesired liver uptake caused by poor physicochemical properties.

163 ding delivery of primary healthcare to urban poor populations is a priority in many low- and middle-i

164 However, survival after mMUD remained poor, possibly related to the severity of chronic GvHD.

165 Small studies reported poor post-partum outcomes among young women living with

166 Widely used algorithms suffer from rather poor precision for these tasks, yielding many false posi

167 Early implementation outcomes often suggest poor PrEP adherence and persistence; however, this inter

168 ive decrease in methane production rates and poor process stability, leading to reactor failure after

169 Idiopathic pulmonary fibrosis (IPF) has a poor prognosis and limited treatment options.

170 ple negative breast cancer (TNBC), which has poor prognosis due to frequent metastasis.

171 Malnutrition is associated with poor prognosis in a wide range of illnesses.

172 Phenotypes of poor prognosis included ADEM-like relapses progressing t

173 that high G9a expression is associated with poor prognosis of CCA patients.

174 independent diagnostic marker predicting the poor prognosis of HCC patients.

175 PEL is an aggressive disease with extremely poor prognosis when treated with conventional chemothera

176 It carries a poor prognosis, in part because its pathogenesis is not

177 ic thyroid cancer (ATC) is aggressive with a poor prognosis, partly because of the immunosuppressive

178 egulated immunoregulation is associated with poor prognosis, whereas early innate signaling and Th1-s

179 ry access issues) and were associated with a poor prognosis, with a very high in-hospital and late de

180 that, unlike acute postinfectious GN, has a poor prognosis.

181 is a brain tumour with high invasiveness and poor prognosis.

182 ession signature, which were associated with poor prognosis.

183 PH) after PEA remains a major determinant of poor prognosis.

184 treatment of ER+ patients (n = 68) predicted poor prognosis.

185 ll carcinomas (RCCs) and carries a decidedly poor prognosis.

186 or gene correlate with high-risk disease and poor prognosis.

187 is the most frequent primary bone tumor with poor prognosis.

188 dvanced colorectal cancer (CRC) have still a poor prognosis.

189 comes after a second IVIg course in GBS with poor prognosis.

190 relatively common cutaneous neoplasm with a poor prognosis.

191 ute myocardial infarction is associated with poor prognosis.

192 cally aggressive malignancy with a uniformly poor prognosis.

193 nt epithelial tumor of the biliary tree with poor prognosis.

194 f a subset of HCC patients with a relatively poor prognosis.

195 nce of 3%-7% progressing to ARF, a marker of poor prognosis.

196 country preparedness to deal with CVDRFs are poor proxies for quality clinical care received by patie

197 excluding nonrandomized trials, or trials of poor quality (Jadad score <3).

198 Poor quality and low repeatability of additively manufac

199 jects recruited, 23 were excluded because of poor quality UBM images.

200 alyses and allow for exclusion of samples of poor quality.

201 -sectional area-a predictor of disability-is poor, questioning the unique role of axonal loss.

202 nous gene segments can be mapped directly to poor RAG binding on their adjacent 12RSSs.

203 nd may suffer from a lack of sensitivity and poor reaction time.

204 phate concentrations to overcome phosphate's poor reactivity with organics in water.

205 that these weak correlations result from the poor reliability of many behavioral measures and the dis

206 rs for primary nonfunction (PNF; n = 37) and poor renal function (estimated glomerular filtration rat

207 d low 1,25D, but not FGF23, levels predicted poor renal outcomes.

208 ions of replicability, which often attribute poor replicability mainly to QRPs.

209 ied protocols and/or trial registration, and poor reporting of adverse events, methods of sequence ge

210 etic studies is often challenging because of poor reporting of key data in study reports.

211 ference in expression level between good and poor responders before starting treatment, allowing to p

212 de new mechanistic insights on the selective poor response of SCC-TAFs to nintedanib.

213 unresectable cholangiocarcinoma (CCA) is its poor response to chemotherapy, which is partly due to re

214 ted levels of IRE1alpha and IGFBPs predict a poor response to drugs inducing unresolvable UPR and pos

215 The identification of both good and poor risk subtypes in patients treated with R-CHOP (ritu

216 The protein is unusual in its poor secretion from cells and its intracellular activity

217 encounter hypoxia or even anoxia leading to poor seed germination and crop establishment.

218 patterns, including stunted bushy shoots and poor seed set.

219 ysts are employed, although accompanied with poor selectivity in hydrotreatment.

220 , male sex, underweight, obesity, education, poor self-rated health, television-viewing time, and hav

221 mitations of current diagnostic tests (i.e., poor sensitivity and delayed results), significant resea

222 s initial triage process is inaccurate, with poor sensitivity and specificity.

223 r close proximity during electrophoresis and poor sensitivity of commonly used staining dye 'coomassi

224 Due to the poor sensitivity of immunofluorescent-antibody assays (I

225 C, including limited immune infiltration and poor sensitivity to ICBs.

226 omes of asthma improvement and worsening but poor sensitivity.

227 le inhalation devices in high-risk, resource-poor settings.

228 public health challenge in several resource poor settings.

229 directional feed-forward interaction between poor sleep and opioid use.

230 Poor sleep behavior appears to have adverse effects on h

231 rimination may contribute to working women's poor sleep health over time, raising concerns about slee

232 roup (<=25 years), higher anxiety level, and poor sleep hygiene.

233 Yet poor sleep may influence opiate use, suggesting a bidire

234 , and causing oxyhemoglobin desaturation and poor sleep quality.

235 monitoring to prevent the adverse effects of poor sleep.

236 iation, with deeper roots on sandy, nutrient-poor soils relative to clayey, nutrient-rich ones.

237 ghtness of Antares in mice is limited by the poor solubility and bioavailability of the NanoLuc subst

238 The poor solubility of chitosan (CS) was improved by succini

239 lities resulting from their poor absorption, poor solubility, high first-pass metabolism, and efficie

240 low-frequency piezo-based transducers offers poor spatial confinement of excitation volume, often big

241 sideration of neointimal thickness yielded a poor specificity of 37.5% and sensitivity 100%.

242 Poor SRH had HR 2.51 (CI: 2.19, 2.88).

243 they have been limited by low solubility and poor stability of active materials.

244 Poor stability of fish hydrolyzed collagen (HC) hampers

245 olites (10%) had an ICC below 0.4 indicating poor stability over time.

246 ay-to-day clock timing of caloric events had poor stability within individuals (~ 3-h variation; ICC

247 Na(+)) is the fundamental root cause for the poor stability, reversibility, and energy efficiency in

248 days from an oxygen-rich state to an oxygen-poor state.

249 Chlamydial LOS was also a poor stimulator of maturation of bone marrow-derived den

250 This is the first study suggesting that the poor stroke recovery in aged mice can be reversed via po

251 proaches has proven to be challenging due to poor structural control at the atomic level.

252 socio-economic issues, predominantly amongst poor subsistence farmers and their families.

253 form during DNA replication, were similarly poor substrates for AAG.

254 cids, or galactolipid-bound fatty acids were poor substrates.

255 e cognition in individuals with DS has had a poor success record.

256 severe mitral annular calcification who are poor surgical candidates.

257 ased on over-represented TFs correlated with poor survival and unfavorable prognostic markers.

258 low SASH1 mRNA expression is associated with poor survival in adenocarcinoma.

259 n of USP11 was significantly associated with poor survival in ERalpha-positive (ERalpha(+)) patients.

260 or response to preoperative chemotherapy and poor survival in patients with CLM.

261 a represents an aggressive tumor type with a poor survival outcome.

262 essive biology, early metastatic spread, and poor survival outcomes.

263 ive form of acute myeloid leukemia (AML) and poor survival rate.

264 cancers is associated with high tumor grade, poor survival, and resistance to chemotherapy.

265 cer, where overexpression is associated with poor survival.

266 lected in human patients and correlated with poor survival.

267 M2 TAM near tumor cells were associated with poor survival.

268 een interpreted as benthic mud-grubbers with poor swimming capabilities and low maneuverability [9-12

269 nerated a high titer of neutralizing Abs but poor T cell responses, whereas Aer induced powerful resp

270 d-organ transplant recipients are limited by poor T(reg) engraftment without host manipulation.

271 superior to IL-6 in distinguishing good from poor therapeutic control (on the basis of white blood ce

272 ted vaccines with adjuvants, frequently have poor thermal stability; heating and/or freezing impairs

273 rogels) have kappa values greater than 2 and poor thermo-mechanical properties(5).

274 itive state (CD39(+)CD69(+)) associated with poor TIL persistence.

275 redicted wine sensory characteristics gave a poor to moderate R(2).

276 s, a mechanism which was likely to drive the poor tolerability.

277 e anaerobic nature of eubacterial cells with poor tolerance for oxygen.

278 lts align with recent evidence of relatively poor tracking of the linguistic signal by the MD regions

279 nd antiretroviral therapy adherence and have poor treatment outcomes.

280 sleep disturbances, which are predictive of poor treatment outcomes.

281 fluence their reactivity toward the electron-poor trichloroacetyl isocyanate.

282 ble for the stability of SOC in N-rich and P-poor tropical forests.

283 neity has proved difficult to resolve due to poor tumor cellularity and extensive genomic instability

284 These limited examples point to a poor understanding of cage catalysis in general, limitin

285 ause of a scarcity of functional studies and poor understanding of how genetic or gene expression lan

286 1 responses to perceptual figures, we have a poor understanding of how the early visual system contri

287 e scale are rare, and consequently we have a poor understanding of how the taxonomic and functional m

288 A major obstacle to this is our poor understanding of the phenotypic and functional hete

289 footprints relative to habitats targeted and poor understanding of the sensitivity, biodiversity, and

290 Given our poor understanding of these risks, many centers have pau

291 rom fundus photography grading, the cause of poor vision appeared to be macular atrophy in 60% and su

292 tis often requiring surgical management with poor visual acuity outcomes.

293 ow within the SVP arterioles and venules and poor visualization of flow in capillaries was noted duri

294 considered in cases of massive bleeding with poor visualization, for salvage therapy, and for diffuse

295 and c (y)pN stages, and LI, VI, PN, and PD (poor vs other).

296 Increased frequency of summer heatwaves and poor water quality are two of the most prevalent and sev

297 ever, its applications are restricted by its poor water solubility.

298 lin-like growth factor-binding protein 7 was poor with respectively an area under the receiver operat

299 skite domains, and the spectral stability is poor, with an undesirable shift (over 7 nm) toward longe

300 ung patients with breast cancer is generally poor, yet considerable differences in clinical outcomes

301 r issues in human islet transplantation: (a) poor yield of islets from donated pancreas tissue and (b